AstraZeneca's financial results were excellent last year despite a poor stock-market performance. The company faces some near-term headwinds, but this won't derail its long-term prospects.

Astrazeneca (AZN) ended the recent trading session at $72.72, demonstrating a -0.45% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss ...

In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ ... particularly popular in the last 15 years, as the US stock market has been the best-performing developed market ...

potentially triggering a positive market reevaluation of the stock. Fresh Astrazeneca information released. What's the impact for investors? Our latest independent report examines recent figures ...

AstraZeneca AZN1.96%increase; green up pointing triangle plans to invest $2.5 billion in China over five years to build a research-and-development center and strike deals with local biotechnology ...